ReviewNature reviews. Endocrinology2014
The management of patients with polycystic ovary syndrome.
Review in Nature reviews. Endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 5 syntheses or guidelines pooled it, 195 citations in OpenAlex.
- Efficacy ofNutrients · 2025Pooled it
- Effects of Metformin on CIMT and FMD in PCOS patients: a systematic review and meta-analysis.BMC women's health · 2024Pooled it
- Prevalence of polycystic ovary syndrome in patients with type 2 diabetes: A systematic review and meta-analysis.Frontiers in endocrinology · 2022Pooled it
- Roles of the Notch Signaling Pathway in Ovarian Functioning.Reproductive sciences (Thousand Oaks, Calif.) · 2021Pooled it
- Metformin Therapy for Acne in Patients with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis.American journal of clinical dermatology · 2021Pooled it
- Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD).Kidney international · 2021Trial
- Insulin Resistance in Polycystic Ovary Syndrome Improved by Chinese Medicine Dingkun Pill (): A Randomized Controlled Clinical Trial.Chinese journal of integrative medicine · 2019Trial
- Polyendocrine metabolic ovarian syndrome (PMOS)/polycystic ovary syndrome (PCOS): current and future trends.The Journal of clinical investigation · 2026Review
- Luteinizing hormone change trajectories in gonadotropin-releasing hormone antagonist protocols are associated with assisted reproductive outcomes: results from a retrospective cohort study.Journal of ovarian research · 2026Article
- Effect of a 5:2 intermittent fasting diet on obese patients with polycystic ovary syndrome.Frontiers in endocrinology · 2026Article
- Combined metabolic-reproductive association and predictive value of AMH and TyG index in PCOS: a single-center retrospective study.Frontiers in endocrinology · 2026Article
- Exploring Microbiome-based Therapy: Bacterial Flavonoid Synthesis as a Novel Approach to PCOS Treatment.Current drug metabolism · 2026Review
- Patients' Experiences of Telehealth-Based Nutrition Interventions for Polycystic Ovary Syndrome in China: Qualitative Descriptive Study.Journal of medical Internet research · 2025Article
- Single cell RNA sequencing reveals the role of local renin-angiotensin system in regulating ovarian physiological cycle and promoting PCOS.Cell death discovery · 2025Article
- Article
- Comparing the Effect of Heat Therapy and Mitochondrial-Targeted Antioxidants in Polycystic Ovarian Syndrome Phenotype Induced by Junk Food Consumption.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Gut-X axis.iMeta · 2025Review
- Article
- Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapy.Nature communications · 2024Article
- Jujuboside A Attenuates Polycystic Ovary Syndrome Based on Estrogen Metabolism Through Activating AhR-mediated CYP1A2 Expression.Reproductive sciences (Thousand Oaks, Calif.) · 2024Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women. The syndrome is typified by its heterogeneous presentation, which includes hirsutism (a function of hypersecretion of ovarian androgens), menstrual irregularity and infertility (that is due to infrequent or absent ovulation). Furthermore, PCOS predisposes patients to metabolic dysfunction and an increased risk of type 2 diabetes mellitus (T2DM). The aetiology of the syndrome has a major genetic component. Obesity exacerbates the insulin resistance that is a feature of PCOS in many women and amplifies the clinical and biochemical abnormalities. In clinical practice, the choice of investigations to be done depends mainly on the presenting symptoms. The approach to management is likewise dependent on the presenting complaint. Symptoms of androgen excess (hirsutism, acne and alopecia) require cosmetic measures, suppression of ovarian androgen function and anti-androgen therapy, alone or in combination. Ovulation rate is improved by diet and lifestyle intervention in overweight individuals but induction of ovulation by, in the first instance, anti-estrogens is usually required. Monitoring of glucose is important in overweight women and/or those with a family history of T2DM. Metformin is indicated for women with impaired glucose tolerance but whether this drug is otherwise useful in women with PCOS remains debatable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.